![Anthony S. Murabito](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Anthony S. Murabito
Corporate Officer/Principal presso New Jersey Society of Health-System Pharmacists
Profilo
Anthony S.
Murabito is a professional with current memberships in the New Jersey Society of Health-System Pharmacists and the Pennsylvania Society of Health-System Pharmacists.
He previously worked as the Group Director of Research & Development at GSK Plc from 1981 to 2000, as well as the Chief Information Officer & Vice President at Human Genome Sciences, Inc. and Cubist Pharmaceuticals LLC.
He also served as the VP of Information Technology & Corporate Services at Transkaryotic Therapies, Inc. from 2001 to 2003.
Murabito received his undergraduate degree from the University of the Sciences in Philadelphia and his graduate degree from Widener University.
Posizioni attive di Anthony S. Murabito
Società | Posizione | Inizio |
---|---|---|
New Jersey Society of Health-System Pharmacists | Corporate Officer/Principal | - |
Pennsylvania Society of Health-System Pharmacists | Corporate Officer/Principal | - |
Precedenti posizioni note di Anthony S. Murabito
Società | Posizione | Fine |
---|---|---|
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2003 |
GSK PLC | Direttore Tecnico/Scientifico/R&S | 01/01/2000 |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Direttore Tecnico/Scientifico/R&S | - |
CUBIST PHARMACEUTICALS INC | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Anthony S. Murabito
University of the Sciences in Philadelphia | Undergraduate Degree |
Widener University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GSK PLC | Health Technology |
Aziende private | 5 |
---|---|
Cubist Pharmaceuticals LLC
![]() Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Transkaryotic Therapies, Inc.
![]() Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
Human Genome Sciences, Inc.
![]() Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
New Jersey Society of Health-System Pharmacists | |
Pennsylvania Society of Health-System Pharmacists |
- Borsa valori
- Insiders
- Anthony S. Murabito